NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science

TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that members of the Company's management will host a conference call and webcast on Monday, March 16, 2026, at 8:00 a.m. ET to present and discuss the topline analysis from the Phase 2 repeated dose clinical study of NS002, the Company's intranasal powder epinephrine product candidate. A question-and-answer session will follow the data presentation. Conference call & webcast info: Monday, March 16, 2026, at 08:00 a.m. ETIndividuals may register for the webcast at

TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced that Company management will participate and present at the upcoming virtual Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com during March 11-12, 2026. Presentation details Date and time: March 11, 2026, 12:30 p.m. ETLocation: Virtual (Register HERE: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5270561/nasus-pharma-ltd-nyse-nsrx)Format: Company presentationSpeaker: Dan Teleman, Chief Execu

TEL AVIV, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Company management will participate in upcoming investor conferences in February and March. Oppenheimer 36th Annual Healthcare Life Sciences Conference Date and time: February 25, 2026, 1:20 p.m. ETLocation: Virtual (register here: https://event.summitcast.com/view/CTtthLh2Bi2D9aYoKpvtEv/KoYPJS8x3zqMuXPHfEHoSY)Format: Company presentationSpeaker: Dan Teleman, Chief Executive Officer BIO Investment & Growth Summit Date and time: March 2, 2026, 10:15 a.m. ETL

TEL AVIV, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that upcoming data for NS002, the Company's investigational intranasal epinephrine powder formulation, will be presented at AAAAI 2026 Annual Meeting, taking place in Philadelphia, PA, USA, February 27 to March 2. "We are excited to share data highlighting NS002's potential for superior epinephrine absorption and robust formulation stability," said Dan Teleman, Chief Executive Officer of Nasus Pharma. "Designed as a needle-free intranasal powder, NS002 aims to deli

TEL AVIV, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the closing of its previously announced private placement of ordinary shares and warrants to purchase ordinary shares for aggregate gross proceeds of approximately $15.0 million, before deducting placement agent fees and other offering expenses. Citizens Capital Markets acted as lead placement agent, and Laidlaw & Company (UK) Ltd. acted as co-placement agent, in connection with the private placement. "We believe this financing strengthens our balance sheet as we a

TEL AVIV, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that it has entered into a securities purchase agreement (the "Agreement") with certain institutional and accredited investors for a private placement of ordinary shares and warrants to purchase ordinary shares for aggregate gross proceeds of approximately $15.0 million, before deducting placement agent fees and other offering expenses. Citizens Capital Markets is acting as lead placement agent, and Laidlaw & Company (UK) Ltd. is acting as co-placement agent

Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to EpiPen® 91% of study participants achieved the 100 pg/ml plasma threshold at 5 minutes with NS002 compared to 67% with EpiPen®   NS002 was well-tolerated with no serious adverse events reported, and a pharmacodynamic response comparable to EpiPen® Full Phase 2 results expected by the end of first quarter of 2026; Pivotal study initiation planned for fourth quarter of 2026 TEL AVIV, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intr

TEL AVIV, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma", "Nasus" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today issued a letter to its shareholders from its Chief Executive Officer, Dan Teleman. Dear Shareholders, 2025 has been a transformational year for Nasus Pharma. We've made considerable progress building a strong, focused company with significant clinical impact, by developing drug delivery products based on our proprietary Nasax powder technology, which has the potential to enhance intranasal drug absorption for improved out

TEL AVIV, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma", "Nasus" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the appointment of Eyal Rubin as Executive Vice President and Chief Financial Officer. Mr. Rubin brings more than two decades of financial leadership experience in global biotechnology and pharmaceutical industries to Nasus Pharma's executive leadership team. Mr. Rubin will lead and oversee Nasus Pharma's financial operations, including corporate finance, financial planning, capital strategy, and investor relations, as

6-K - Nasus Pharma Ltd (0002029039) (Filer)

6-K - Nasus Pharma Ltd (0002029039) (Filer)

F-1 - Nasus Pharma Ltd (0002029039) (Filer)

D - Nasus Pharma Ltd (0002029039) (Filer)

6-K - Nasus Pharma Ltd (0002029039) (Filer)

6-K - Nasus Pharma Ltd (0002029039) (Filer)

6-K - Nasus Pharma Ltd (0002029039) (Filer)

6-K - Nasus Pharma Ltd (0002029039) (Filer)

6-K - Nasus Pharma Ltd (0002029039) (Filer)

6-K - Nasus Pharma Ltd (0002029039) (Filer)

TEL AVIV, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma", "Nasus" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the appointment of Eyal Rubin as Executive Vice President and Chief Financial Officer. Mr. Rubin brings more than two decades of financial leadership experience in global biotechnology and pharmaceutical industries to Nasus Pharma's executive leadership team. Mr. Rubin will lead and oversee Nasus Pharma's financial operations, including corporate finance, financial planning, capital strategy, and investor relations, as

TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that members of the Company's management will host a conference call and webcast on Monday, March 16, 2026, at 8:00 a.m. ET to present and discuss the topline analysis from the Phase 2 repeated dose clinical study of NS002, the Company's intranasal powder epinephrine product candidate. A question-and-answer session will follow the data presentation. Conference call & webcast info: Monday, March 16, 2026, at 08:00 a.m. ETIndividuals may register for the webcast at